Loading...
Market
How will Suven Pharma's stock performance compare to the pharma sector by the end of 2024?
2
Resolution / Starting Odds
Outperforms by more than 5% • 25%
Outperforms by 0% - 5% • 25%
Underperforms by 0% - 5% • 25%
Underperforms by more than 5% • 25%
BSE sector performance data
Story
Suven Pharma Hits All-Time High of Rs 1,245 After US FDA Closes Inspection
Sep 9, 2024, 04:45 AM
Suven Pharma's Hyderabad-based manufacturing facility, operated by its subsidiary Casper Pharma, received an Establishment Inspection Report (EIR) from the US FDA. The inspection, conducted between July 8-12, 2024, was categorized as Voluntary Action Indicated (VAI) and has been deemed closed. Following this disclosure, Suven Pharma's share price surged by up to 3.67%, reaching an all-time high of Rs 1,245 per share on the BSE.
View original story
Similar markets
Outperforms all • 25%
Outperforms some • 25%
Matches performance • 25%
Underperforms all • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Outperforms • 33%
Performs similarly • 34%
Underperforms • 33%
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Significantly outperform • 25%
Slightly outperform • 25%
Match sector performance • 25%
Underperform • 25%
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Significantly underperforms • 25%
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
Outperforms by more than 5% • 25%
Outperforms by 0% to 5% • 25%
Underperforms by 0% to 5% • 25%
Underperforms by more than 5% • 25%